Prostaglandin A1 inhibits avian influenza virus replication at a postentry level: Effect on virus protein synthesis and NF-κB activity

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 91, Issue 6, 2014, Pages 311-323

  Carta, Stefania ^a   La Frazia, Simone ^a   Donatelli, Isabella ^b   Puzelli, Simona ^b   Rossi, Antonio ^c   Santoro, M Gabriella ^a,c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

Author keywords

Antiviral; Cyclopentenone prostanoids; Heat shock proteins; NF kappaB

Indexed keywords

HEAT SHOCK PROTEIN 70; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROSTAGLANDIN A1; VIRUS PROTEIN; ANTIVIRUS AGENT; PROSTAGLANDIN A;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; AVIAN INFLUENZA; BIOLOGICAL ACTIVITY; BIOLOGICAL FUNCTIONS; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N9; INFLUENZA VIRUS A H7N1; MICROTUBULE ASSEMBLY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SYNTHESIS; TRANSCRIPTION INITIATION; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; BIOSYNTHESIS; CELL LINE; CHICKEN; DOG; DRUG EFFECTS; LUNG ALVEOLUS; MDCK CELL LINE; METABOLISM; PHYSIOLOGY;

AVES; AVIAN INFLUENZA VIRUS; INFLUENZA A VIRUS;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CHICKENS; DOGS; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H7N1 SUBTYPE; MADIN DARBY CANINE KIDNEY CELLS; NF-KAPPA B; PROSTAGLANDINS A; PULMONARY ALVEOLI; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84922062187     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2014.07.009     Document Type: Article

References (59)

1. Wright P.F., Neumann G., Kawaoka Y. Orthomyxoviruses. Fields Virology 2007, 1691-1740. Lippincott Williams & Wilkins, Philadelphia. D.M. Knipe, P.M. Howley (Eds.).
2. Horimoto T., Kawaoka Y. Influenza: lessons from past pandemics, warnings from current incidents. Nat. Rev. Microbiol. 2005, 3:591-600.
3. Palese P., Shaw M.L. Orthomyxoviridae: the viruses and their replication. Fields Virology 2007, 1647-1689. Lippincott Williams & Wilkins, Philadelphia. D.M. Knipe, P.M. Howley (Eds.).
4. Watanabe Y., Ibrahim M.S., Suzuki Y., Ikuta K. The changing nature of avian influenza A virus (H5N1). Trends Microbiol. 2012, 20:11-20.
5. Webster R.G., Bean W.J., Gorman O.T., Chambers T.M., Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol. Rev. 1992, 56:152-179.
6. Neumann G., Shinya K., Kawaoka Y. Molecular pathogenesis of H5N1 influenza virus infections. Antivir. Ther. 2007, 12:617-626.
7. Taubenberger J.K., Morens D.M. The pathology of influenza virus infections. Annu. Rev. Pathol. 2008, 3:499-522.
8. Cheung C.Y., Poon L.L., Lau A.S., et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease?. Lancet 2002, 360:1831-1837.
9. Wong S.S., Yuen K.Y. Avian influenza virus infections in humans. Chest 2006, 129:156-168.
10. Bernasconi D., Amici C., La Frazia S., Ianaro A., Santoro M.G. The IκB kinase is a key factor in triggering influenza A virus-induced inflammatory cytokine production in airway epithelial cells. J. Biol. Chem. 2005, 280:24127-24134.
11. Santoro M.G., Rossi A., Amici C. NF-κB and virus infection: who controls whom. EMBO J. 2003, 22:2552-2560.
12. Vallabhapurapu S., Karin M. Regulation and function of NF-κB transcription factors in the immune system. Annu. Rev. Immunol. 2009, 27:693-733.
13. Karin M. The IkappaB kinase-a bridge between inflammation and cancer. Cell Res. 2008, 18:334-342.
14. Bai T., Zhou J., Shu Y. Serologic study for influenza A (H7N9) among high-risk groups in China. N. Engl. J. Med. 2013, 368:2339-2340.
15. Liu D., Shi W., Shi Y., et al. Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: phylogenetic, structural, and coalescent analyses. Lancet 2013, 381:1926-1932.
16. Santoro M.G. Antiviral activity of cyclopentenone prostanoids. Trends Microbiol. 1997, 5:276-281.
17. Donatelli I., Campitelli L., Di Trani L., et al. Characterization of H5N2 influenza viruses from Italian poultry. J. Gen. Virol. 2001, 82:623-630.
18. La Frazia S., Amici C., Santoro M.G. Antiviral activity of proteasome inhibitors in herpes simplex virus-1 infection: role of nuclear factor-kappaB. Antivir. Ther. 2006, 11:995-1004.
19. Rossignol J.F., La Frazia S., Chiappa L., Ciucci A., Santoro M.G. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at post-translational level. J. Biol. Chem. 2009, 284:29798-29808.
20. Amici C., Belardo G., Rossi A., Santoro M.G. Activation of IkappaB kinase by herpes simplex virus type 1. A novel target for anti-herpetic therapy. J. Biol. Chem. 2001, 276:28759-28766.
21. Rossi A., Kapahi P., Natoli G., et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 2000, 403:103-108.
22. 2 is a potent inhibitor of influenza A virus replication. Antimicrob. Agents Chemother. 2000, 44:200-204.
23. Santoro M.G., Favalli C., Mastino B., Jaffe B.M., Esteban M., Garaci E. Antiviral activity of a synthetic analog of prostaglandin A in mice infected with influenza A virus. Arch. Virol. 1988, 99:89-100.
24. Amici C., Santoro M.G. Suppression of virus replication by prostaglandin A is associated with heat shock protein synthesis. J. Gen. Virol. 1991, 72:1877-1885.
25. 1: a translational block associated with HSP70 synthesis. J. Virol. 1994, 68:6890-6899.
26. Amici C., Rossi A., Costanzo A., et al. Herpes simplex virus disrupts NF-kappaB regulation by blocking its recruitment on the IkappaBalpha promoter and directing the factor on viral genes. J. Biol. Chem. 2006, 281:7110-7117.
27. Amici C., Belardo G., Rozera C., Bernasconi D., Santoro M.G. Inhibition of herpesvirus-induced HIV-1 replication by cyclopentenone prostaglandins: role of IkappaB kinase (IKK). AIDS 2004, 18:1271-1280.
28. de Jong J.C., Claas E.C., Osterhaus A.D., Webster R.G., Lim W.L. A pandemic warning?. Nature 1997, 389:554.
29. Gao R., Cao B., Hu Y., et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N. Engl. J. Med. 2013, 368:1888-1897.
30. Chen Y., Liang W., Yang S., et al. Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome. Lancet 2013, 381:1916-1925.
31. Hu Y., Lu S., Song Z., et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 2013, 381:2273-2279.
32. Subbarao K., Joseph T. Scientific barriers to developing vaccines against avian influenza viruses. Nat. Rev. Immunol. 2007, 7:267-278.
33. Regoes R.R., Bonhoeffer S. Emergence of drug-resistant influenza virus: population dynamical considerations. Science 2006, 302:389-391.
34. Boltz D.A., Aldridge J.R., Webster R.G., Govorkova E.A. Drugs in development for influenza. Drugs 2010, 70:1349-1362.
35. Hayden F.G., Hay A.J. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr. Top. Microbiol. Immunol. 1992, 176:119-130.
36. Gubareva L.V., Webster R.G., Hayden F.G. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antivir. Res. 2002, 53:47-61.
37. Cheung C.L., Rayner J.M., Smith G.J., et al. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J. Infect. Dis. 2006, 193:1626-1629.
38. Hai R., Schmolke M., Leyva-Grado V.H., et al. Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. Nat. Commun. 2013, 4:2854. 10.1038/ncomms3854/www.nature.com/naturecommunications.
39. Ludwig S. Targeting cell signalling pathway to fight the flu: towards a paradigm change in anti-influenza therapy. J. Antimicrob. Chemother. 2009, 64:1-4.
40. Vane J., O'Grady J. Therapeutic Applications of Prostaglandins 1993, 288. Edward Arnold, London.
41. Santoro M.G., Benedetto A., Carruba G., Garaci E., Jaffe B.M. Prostaglandin A compounds as antiviral agents. Science 1980, 209:1032-1034.
42. Santoro M.G., Amici C., Rossi A. Role of heat shock proteins in viral infection. Prokaryotic and Eukaryotic Heat Shock Proteins in Infectious Disease 2009, 51-84. Springer, Heidelberg. A.G. Pockley, S.K. Calderwood, M.G. Santoro (Eds.).
43. Hooper P.L., Hightower L.E., Hooper P.L. Loss of stress response as a consequence of viral infection: implications for disease and therapy. Cell Stress Chaperones 2012, 17:647-655.
44. Collins P.L., Hightower L.E. Newcastle disease virus stimulates the cellular accumulation of stress (heat shock) mRNAs and proteins. J. Virol. 1982, 44:703-707.
45. Rossi A., Elia G., Santoro M.G. 2-cyclopenten-1-one, a new inducer of heat shock protein 70 with antiviral activity. J. Biol. Chem. 1996, 271:32192-32196.
46. Rossi A., Elia G., Santoro M.G. Inhibition of nuclear factor kappa B by prostaglandin A1: an effect associated with heat shock transcription factor activation. Proc. Natl. Acad. Sci. USA 1997, 94:746-750.
47. Unoshima M., Iwasaka H., Eto J., Takita-Sonoda Y., Noguchi T., Nishizono A. Antiviral effects of geranylgeranylacetone: enhancement of MxA expression and phosphorylation of PKR during influenza virus infection. Antimicrob. Agents Chemother. 2003, 47:2914-2921.
48. Li G., Zhang J., Tong X., Liu W., Ye E. Heat shock protein 70 inhibits the activity of Influenza A virus ribonucleoprotein and blocks the replication of virus in vitro and in vivo. PLoS One 2011, 6:e16546.
49. Hirayama E., Atagi H., Hiraki A., Kim J. Heat shock protein 70 is related to thermal inhibition of nuclear export of the influenza virus ribonucleoprotein complex. J. Virol. 2004, 78:1263-1270.
50. Serhan C.N., Haeggström J.Z., Leslie C.C. Lipid mediator networks in cell signaling: update and impact of cytokines. FASEB J. 1996, 10:1147-1158.
51. Lawrence T., Willoughby D.A., Gilroy D.W. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat. Rev. Immunol. 2002, 2:787-795.
52. Calderwood S.K., Bornstein B., Farnum E.K., Stevenson M.A. Heat shock stimulates the release of arachidonic acid and the synthesis of prostaglandins and leukotriene B4 in mammalian cells. J. Cell Physiol. 1989, 141:325-333.
53. Gilroy D.W., Colville-Nash P.R., Willis D., Chivers J., Paul-Clark M.J., Willoughby D.A. Inducible cyclooxygenase may have anti-inflammatory properties. Nat. Med. 1999, 5:698-701.
54. Offenbacher S., Odle B.M., Van Dyke T.E. The use of crevicular fluid prostaglandin E2 levels as a predictor of periodontal attachment loss. J. Periodontal Res. 1986, 21:101-112.
55. Carey M.A., Bradbury J.A., Seubert J.M., Langenbach R., Zeldin D.C., Germolec D.R. Contrasting effects of cyclooxygenase-1 (COX-1) and COX-2 deficiency on the host response to influenza A viral infection. J. Immunol. 2005, 175:6878-6884.
56. Lee M.Y., Cheung C.Y., Peiris J.S. Role of cyclooxygenase-2 in H5N1 viral pathogenesis and the potential use of its inhibitors. Hong Kong Med. J. 2013, 19(Suppl 4):29-35.
57. Kang Y.J., Mbonye U.R., DeLong C.J., Wada M., Smith W.L. Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradation. Prog. Lipid Res. 2007, 46:108-125.
58. Shield M.J. Novel applications of misoprostol. Pharmacol. Ther. 1995, 65:125-147.
59. Sinclair S.B., Greig P.D., Blendis L.M., et al. Biochemical and clinical response of fulminant viral hepatitis to administration of prostaglandin E. A preliminary report. J. Clin. Investig. 1989, 84:1063-1069.